BiotechTube

TR701 FA

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Major Cutaneous Abscess

Conditions

Major Cutaneous Abscess, Cellulitis, Erysipelas

Trial Timeline

Feb 15, 2012 → Aug 27, 2012

NCT ID
NCT01519778

About TR701 FA

TR701 FA is a phase 2 stage product being developed by Merck for Major Cutaneous Abscess. The current trial status is completed. This product is registered under clinical trial identifier NCT01519778. Target conditions include Major Cutaneous Abscess, Cellulitis, Erysipelas.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01519778Phase 2Completed

Competing Products

20 competing products in Major Cutaneous Abscess

See all competitors
ProductCompanyStageHype Score
Duloxetine HydrochlorideEli LillyPre-clinical
23
LY2216684Eli LillyPhase 1
33
LY2216684Eli LillyPhase 1
33
DuloxetineEli LillyPhase 3
77
LY2216684 + DigoxinEli LillyPhase 1
33
Duloxetine + ParoxetineEli LillyPhase 3
77
Duloxetine + placeboEli LillyPhase 3
77
LY2216684 + Placebo + EscitalopramEli LillyPhase 2
52
FK949EAstellas PharmaPhase 1
33
quetiapine extended release (XR) + PlaceboAstellas PharmaPhase 2
52
FK949EAstellas PharmaPhase 1
33
FK949EAstellas PharmaPhase 1
33
FK949EAstellas PharmaPhase 1
33
Mirtazapine TabletsSun PharmaceuticalApproved
85
ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1Ono PharmaceuticalPhase 2
52
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
Pramipexole ER + EscitalopramCiplaPhase 2
52
LY2216684 + SertralineEli LillyPhase 1
33
LY2216684 + Placebo + LorazepamEli LillyPhase 1
33
LY2216684 + SSRIEli LillyPhase 3
77

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85